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http://dx.doi.org/10.1016/j.jmii.2012Background: Gram-negative bacilli causing community-onset urinary tract infections (CoUTIs) are
getting increasingly resistant to antimicrobial agents. Clinical significance and risk factors of the
acquisition of antimicrobial-nonsusceptible pathogens are still under investigation.
Methods: A prospective study was performed in the medical wards of two hospitals in southern
Taiwan between August 2009 and January 2012. Patients were enrolled if they were aged >18,
admitted through the emergency department, and had CoUTI due to Enterobacteriaceae isolates.
Results: Overall 136 adults with CoUTI were enrolled. Their mean age was 67 years and females
were predominant (68.4%). Comorbidities, such as diabetes mellitus (30.1%) and hypertension
(54.4%), were common. Escherichia coli (111, 81.6%) was the predominant species, followed by
Klebsiella pneumoniae (11, 8.1%), and Proteus mirabilis (7, 5.1%). Nine (8.0%) of E. coli isolates
and 5 (45%) of K. pneumoniae isolates had extended-spectrum b-lactamase (ESBL) production.
Out of 122 non-ESBL producing isolates, 35 (28.7%) and 31 (25.4%) were nonsusceptible to levoflox-
acin and cefazolin, respectively. In the multivariate analysis, several clinical characters wereof Internal Medicine, National Cheng Kung University Hospital, No. 138 Sheng Li Road, Tainan 70403,
il.com (W.-C. Ko).
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198 Y.-H. Wu et al.found to be independently associated with CoUTIs due to levofloxacin-nonsusceptible (i.e. males,
recent hospitalization, underlying old stroke, diabetes mellitus, and altered consciousness, or
absence of chills, pyuria, or tachycardia), cefazolin-nonsusceptible (i.e. males, recent hospitali-
zation, underlying old stroke, absence of fever or chills), or ESBL-producing isolates (i.e. recent
hospitalization or antimicrobial therapy). All patients survived and discharged. However, the
patients with CoUTIs due to levofloxacin-nonsusceptible (16.1 vs. 7.5 days, p < 0.01), cefazolin-
nonsusceptible (15.4 vs. 8.4 days, p < 0.01) or ESBL-producing (16.7 vs. 9.6 days; p < 0.01) path-
ogens had a longer hospitalization stay than those due to their susceptible comparators.
Conclusion: Several host factors were recognized to be independently associated with the acqui-
sition of UTIs due to levofloxacin- or cefazolin- nonsusceptible, or ESBL-producing Gram-negative
bacilli. The clinical impact of UTIs due to nonsusceptible uropathogens is that they result in the
prolongation of hospital stays.
Copyright ª 2012, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Urinary tract infection (UTI) is the most common bacterial
infection encountered in the ambulatory care settling in
the United States, and is associated with significant
morbidity and mortality.1,2 The global surveillance study
called SMART revealed, that among Enterobacteriaceae
isolates from complicated UTIs, there was significant anti-
microbial resistance to levofloxacin/ciprofloxacin (33%) and
extended spectrum cephalosporins (>30%) in the Asia-
Pacific region.2 In addition, high prevalence rate of
extended-spectrum b-lactamase (ESBL) production among
uropathogenic Escherichia coli isolates was seen. Increasing
fluoroquinolone resistance is another critical issue since
fluoroquinolones (FQs) have been recommended as the
drugs of choice for empirical treatment of uncomplicated
and complicated UTIs caused by trimethoprim-
sulfamethoxazole-resistant uropathogens.3
The resistance issue among uropathogens has become
a global problem, necessitating consensus on revising the
guidelines of empirical treatment of UTIs.4,5 There are
many articles discussing the risk factors of fluo-
roquinolone resistance among E. coli isolates from UTI.6,7
In this study, we conducted a prospective study to identify
host-related risk factors for community-onset UTI (CoUTI)
due to levofloxacin- or cefazolin-nonsusceptible isolates
or uropathogens with ESBL production in adults admitted
to medical wards. Also clinical impact of UTIs due to
antimicrobial-nonsusceptible pathogens was investigated.Materials and methods
A prospective study was conducted at medical wards of
National Cheng-Kung University Hospital, Douliu branch of
NCKUH, and Tainan Hospital, Department of Health, Exec-
utive Yuan, at southern Taiwan between August 2009 and
January 2012. Hospitalized patients were enrolled if they
met the following criteria: they were older than 18 years,
admitted through the emergency department and diag-
nosed as having CoUTI due to one species of Enter-
obacteriaceae. There were 164 cases enrolled into the
study, and 28 were excluded because of polymicrobialinfections or no available causative isolates for antibiotic
susceptibility tests. Clinical information including age,
gender, residence in nursing home, recent hospitalization
within 6 months, recent antibiotic exposure within 60 days,
underlying diseases (including end-stage renal disease, old
stroke, diabetes mellitus, hypertension, chronic kidney
disease, renal stone, or chronic hepatitis), and the use of
indwelling urinary catheter, were retrieved from chart
reviews or electronic databases, or by interviewing with
their care-givers. The primary end-point for clinical impact
was the duration of hospitalization, since there were no
fatalities until discharge.
Recurrent UTI was defined if the individual had at least
one episode of UTI within 1 year. Complicated UTI was
defined as the occurrence of UTI in individuals with func-
tional or structural abnormalities of the genitourinary
tract. Concurrent bacteremia was defined as the presence
of the identical uropathogen with the same antibiogram in
blood cultures. Abnormal liver function was defined as
elevated serum levels of aspartate transaminase (>39 U/L)
or alanine aminotransferase (>54 U/L). Acute kidney injury
was referred to if there at least was a 2-fold increase in
serum creatinine level.
This study was supported by the National Cheng Kung
University Hospital Research Committee and approved by
the institutional review board of National Cheng Kung
University Hospital and Tainan hospital, Department of
Health, Executive Yuan. Informed consents were obtained
from participating patients.
Bacterial cultures and antimicrobial susceptibility
tests
Fresh urine samples were delivered to the laboratory and
were processed as per standard procedure. Blood cultures
were processed using the automated blood culture system
(VITEK 2 complete ID/AST Automation system; bioMe´rieux,
Mercy l’Etoile, France). Urine samples were plated on the
eosin methylene blue agar and the isolated microorganisms
were categorized by Gram staining. Antibiotic susceptibility
testing was determined using the disk diffusion method in
accordance with the criteria from the Clinical and Labora-
tory Standards Institute, M100-S21.8 Drug disks tested for the
Table 1 Clinical characteristics of 136 adults with
community-onset urinary tract infection (UTI) caused by
Enterobacteriaceae
Characteristics Number (%)
Recurrent UTI 27 (19.9)
Hospitalization within 6 mo 54 (39.7)
Antibiotics exposure within 60 d 24 (17.6)
Co-morbidity
Hypertension 74 (54.4)
Diabetes mellitus 41 (30.1)
Old stroke 35 (25.7)
Chronic renal disease 18 (13.2)
Chronic hepatitis 18 (13.2)
Renal stones 2 (1.5)
Diagnosis
UTI only 38 (27.9)
Complicated UTI only 23 (16.9)
UTI and bacteremia 38 (27.9)
Complicated UTI and bacteremia 37 (27.2)
Symptoms and signs
Fever 100 (74.1)
Chills/rigor 48 (35.8)
Tachycardia 45 (33.1)
Pyuria 125 (94.0)
Hematuria 77 (57.9)
Thrombocytopenia 18 (13.4)
Acute kidney injury 18 (13.4)
Structural abnormality of urinary tract 30 (22.4)
Functional abnormality of urinary tract 20 (14.9)
Indwelling urinary catheter 12 (9.0)
Figure 1. Bacterial species and isolate numbers of 136 uro-
pathogens in the present study.
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cillin/sulbactam, gentamicin, amikacin, cefazolin, cefurox-
ime, ceftriaxone, and levofloxacin. In the present study,
nonsusceptibility arbitrarily refers to the category of inter-
mediate and resistant results, obtained using the disc
diffusion method. A difference of at least 5 mm between the
zone diameters of either cefotaxime or ceftazidime disks
and their respective cephalosporin/clavulanate disks was
taken to be the phenotypic confirmation of ESBL production.
Statistical methods
Descriptive statistics, including means, standard devia-
tions, and ranges, were used to analyze continuous vari-
ables, whereas percentages and confidence intervals were
used to analyze categorical variables. Independent t test
was used for continuous variables. A Chi-square test or
Fisher’s exact test was used for categorical variables. The
variables in bivariate analyses with a p  0.1 were included
in a multivariate analysis, which was performed using
a logistic regression model to identify factors that inde-
pendently and significantly affected the outcome. A p-
value <0.05 was considered to be statistically significant.
All statistical analyses were done using SPSS 15 (SPSS Inc.,
Chicago, IL, USA) for Windows.
Results
A total of 136 adults with microbiologically documented
CoUTIs were enrolled during the study period; there were
seven patients from Tainan Hospital, 11 from the Douliu
Branch, NCKUH, and 118 from NCKUH. Basic characters of
the 136 patients are shown in Table 1. There were 93
(68.4%) female patients. The mean age was 67 years with
an age range of 19 to 91 years. A recent history of hospi-
talization within 6 months was noted in 54 (39.7%) patients
and recent antibiotic exposure within 60 days in 24 (17.6%)
patients. About 20% (27 patients, 19.9%) had recurrent UTI.
Structural and functional abnormalities were present in 30
(22.4%) and 20 (14.9%) patients, respectively. Indwelling
urinary catheter was present in situ in 12 (9.0%) patients.
Common comorbidities were hypertension (54.4%) and
diabetes mellitus (30.1%).
Usual symptoms or signs at presentation included pyuria
(94%), fever (74.1%), and hematuria (57.9%). The episode of
UTI in 60 (44.1%) patients was considered to be compli-
cated, of which 61.7% (37 patients) had concurrent
bacteremia. Out of all patients with UTI, 75 (55.1%)
patients had bacteremia (Table 1). Of the Enter-
obacteriaceae pathogens isolated, E. coli (111, 82%) was
the predominant species, followed by Klebsiella pneumo-
niae (11, 8%) and Proteus spp. (8, 6%). Out of 136 patients,
there were 75 (55.1%) patients with bacteremia due to
E. coli (62 patients, 83%), K. pneumoniae (9, 12%), Proteus
spp. (3, 4%), and Klebsiella oxytoca (1, 1%) (Fig. 1).
There were 14 (10.3%) ESBL-producing Enter-
obacteriaceae isolates, of which all but one (13, 92.9%)
were resistant to levofloxacin. Of 122 non-ESBL producing
clinical isolates, 35 (28.7%), 31 (25.4%), and 16 (13.1%) were
nonsusceptible to levofloxacin, cefazolin, and ceftriaxone,
respectively. Among 111 E. coli isolates, which was thepredominant species, 38 (34%) isolates were nonsusceptible
to levofloxacin, 28 (25%) to cefazolin, 22 (20%) to cefurox-
ime, and 20 (18%) to ceftriaxone.Clinical variables associated with levofloxacin
nonsusceptibility among uropathogens from
patients with UTI
Clinical features of 136 patients were compared according
to the levofloxacin susceptibility of isolated pathogens
Table 2 Univariate analysis of clinical variables associated with levofloxacin nonsusceptibility in uropathogens obtained from
adults with urinary tract infection (UTI)
Risk factors Susceptible
n Z 88 (%)
Nonsusceptible
n Z 48 (%)
OR 95% CI p
Age >65 y 48 (54.5) 37 (77.1) 2.8 1.3e6.2 0.01
Male gender 23 (26.1) 20 (41.7) 2.0 1.0e4.3 0.08
Recurrent UTI 12 (13.6) 15 (31.3) 2.9 1.2e6.8 0.02
Prior hospitalization in the past 6 mo 19 (21.6) 35 (72.9) 9.8 4.3e22.1 <0.01
Prior antibiotic in the past 60 d 8 (9.1) 16 (33.3) 5.0 1.9e12.8 <0.01
Urinary tract structure abnormality 19 (21.8) 11 (23.4) 1.1 0.5e2.5 0.83
Urinary function abnormality 8 (9.2) 12 (25.5) 3.4 1.3e9.0 0.02
Indwelling urinary catheter 3 (3.4) 9 (19.1) 6.6 1.7e25.9 <0.01
Co-morbidity
Old stroke 12 (13.6) 23 (47.9) 5.8 2.5e13.4 <0.01
Diabetes mellitus 18 (20.7) 23 (47.9) 3.5 1.6e7.6 <0.01
Hypertension 47 (53.4) 27 (56.3) 1.1 0.6e2.3 0.86
Benign prostate hypertrophy 11 (12.5) 6 (12.5) 1.0 0.3e2.9 1.0
Renal disease 10 (11.4) 8 (16.7) 1.6 0.6e4.3 0.43
Renal stones 8 (9.2) 4 (8.3) 0.9 0.3e3.2 1.0
Solid tumor 4 (4.5) 6 (12.5) 3.0 0.8e11.2 0.17
Presentations of UTI
Altered consciousness 10 (11.5) 12 (25.5) 2.6 1.0e6.7 0.05
Urinary symptoms 56 (64.4) 14 (29.8) 0.2 0.1e0.5 <0.01
Chills 39 (44.8) 9 (19.1) 0.3 0.1e0.7 <0.01
Fever 71 (81.6) 29 (60.4) 0.3 0.2e0.8 0.01
Pyuria 81 (93.1) 44 (95.7) 1.6 0.3e8.4 0.71
Hematuria 59 (67.8) 18 (39.1) 0.3 0.2e0.6 <0.01
Tachycardia 29 (33.3) 16 (34) 1.0 0.5e2.2 1.0
Thrombocytopenia 11 (12.6) 7 (14.9) 1.2 0.4e3.4 0.79
Abnormal liver function 8 (9.1) 5 (10.6) 1.2 0.4e3.9 0.77
Acute kidney injury 10 (11.4) 8 (17) 1.6 0.6e4.4 0.43
CI Z confidence interval; OR Z odds ratio.
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occurred more often in the elderly. Patients with diabetes
mellitus and a prior history of stroke were more likely to be
infected by levofloxacin-susceptible isolates.
Patients with any one of the following: prior history of
UTI, hospitalization, nursing home residence or regular visit
to dialysis centers within 6 months, recent exposure to
antibiotics in the previous 2 months, functional abnormal-
ities of urinary tract, or indwelling urinary catheter, were
more likely to be infected by levofloxacin-nonsusceptible
isolates (Table 2).
Clinical isolates with levofloxacin nonsusceptibility were
significantly associated with nonsusceptibiluty to other anti-
biotics, including ampicillin, ampicillin/sulbactam, genta-
micin, cephalosporins, and associated with ESBL production
(Fig. 2). In contrast, typical presentations of UTIs, such as
dysuria, frequency, urgency, flank pain, fever, chills, or
hematuria, were more often noted in those with UTIs due to
levofloxacin-susceptible isolates. There were no differences
in terms of the frequency of pyuria, thrombocytopenia,
abnormal liver enzymes, or acute kidney injury between
patients with UTI due to levofloxacin-susceptible and their
corresponding nonsusceptible comparators.
Using the multivariate analysis, recent hospitalization or
nursing home residence within 6 months, diabetes mellitus,
male, and old stroke were independently associated withthe acquisition of levofloxacin-nonsusceptible uropath-
ogens (Table 3). However, patients presenting with fever,
hematuria, and urinary symptoms (such as burning sensa-
tion, flank soreness, frequency and urgency), were less
likely to be infected with levofloxacin-nonsusceptible uro-
pathogens (Table 3).Clinical variables associated with cefazolin
nonsusceptibility among uropathogens from
patients with UTI
Likewise UTIs due to cefazolin-nonsusceptible isolates
occurred more often in males than females (48.8%, 21/43 vs.
23.7%, 22/93; p< 0.01). Prior stroke (51.2%, 22/43 vs. 14.0%,
13/93; p < 0.01), recent hospitalization within 6 months
(76.7%, 33/43 vs. 22.6%, 21/93; p < 0.01), and indwelling
urinary catheter (16.3%, 7/43 vs. 5.4%, 5/93; p < 0.05) were
more often associated with UTIs due to cefazolin-
nonsusceptible isolates. Cefazolin-nonsusceptible isolates
were more often associated with nonsusceptibility to other
antibiotics, including ampicillin, ampicillin/sulbactam,
gentamicin, cefuroxime, and ceftriaxone (Fig. 3). Further-
more, multivariate analysis revealed that recent hospitali-
zation [adjusted odds ratio (aOR) 8.9], male gender (aOR
4.6) and old stroke (aOR 3.9) were independently related to
Figure 2. The nonsusceptible rates of eight antimicrobial agents among 122 isolates that were not extended-spectrum b-lac-
tamase-producing uropathogens, stratified by levofloxacin susceptibility (*indicates a significant difference with p < 0.05).
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presented with urinary symptoms and chills were less likely
to be infected with cefazolin-nonsusceptible pathogens
(Table 3).Clinical variables associated with ESBL production
among E. coli, Klebsiella and Proteus species from
patients with UTI
Among 131 isolates of E. coli, Klebsiella and Proteus spp.,
which would be tested for ESBL-production phenotype if
decreased zone diameters of cefotaxime or ceftazidimeTable 3 Multivariate analysis of clinical variables associated w
spectrum beta-lactamase (ESBL) production in uropathogens obta
Risk factors Levofloxacin
nonsusceptibility
aOR 95% CI p
Male gender 3.1 1.1e8.6
Prior hospitalization in the past 6 months 4.8 1.8e12.9 <
Prior antibiotic in the past 60 days
Co-morbidity
Old stroke 3.1 1.1e8.2
Diabetes mellitus 3.8 1.5e9.9 <
Presentations of urinary tract infection
Altered consciousness 3.2 1.0e9.7
Chills 0.4 0.2e0.9
Fever
Pyuria 0.3 0.1e0.7 <
Tachycardia 0.3 0.1e0.6 <
aOR Z adjusted odds ratio; CI Z confidence interval.
a The analytic population of ESBL production is the patients with Udiscs were noted, according to the recommendations of
CLSI, clinical characters of 14 (10.7%) ESBL-producing
isolates were compared with those of 117 isolates without
ESBL. Patients with ESBL-producer UTIs more often had
recurrent UTI (8/14, 57.1% vs. 18/117, 15.4%; p < 0.01),
prior hospitalization within 6 months (12/14, 85.7% vs. 39/
117, 33.3%; p < 0.01), prior antibiotics within 60 days (8/
14, 57.1% vs. 16/117, 12.7%; p < 0.01), urinary function
abnormalities (7/14, 50% vs. 12/117, 10.3%; p < 0.01),
indwelling urinary catheter (5/14, 35.7% vs. 7/117, 6%;
p < 0.01), underlying old stroke (8/14, 57.1% vs. 26/117,
22.2%; p < 0.01), and receipt of immunosuppressive
therapy (2/14, 14.3% vs. 1/117, 0.9; p Z 0.03) than thoseith levofloxacin or cefazolin nonsusceptibility and extended-
ined from adults with urinary tract infection
Cefazolin
nonsusceptibility
ESBL productiona
aOR 95% CI p aOR 95% CI p value
0.03 4.6 1.7e12.2 <0.01
0.01 8.9 3.4e23.6 <0.01 7.4 1.5e37.6 0.02
4.2 1.2e14.8 0.03
0.03 3.9 1.4e10.6 <0.01
0.01
0.04
0.03 0.4 0.2e1.0 0.04
0.3 0.1e0.8 0.01
0.01
0.01
TIs due to Escherichia coli, Klebsiella or Proteus species.
Figure 3. The nonsusceptible rates of eight antimicrobial agents among 122 isolates that were not extended-spectrum b-lac-
tamase-producing uropathogens, stratified by levofloxacin susceptibility (*indicates a significant difference with p < 0.05).
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analysis, only recent hospitalization and antimicrobial
therapy were independently related to ESBL-producer UTIs
(Table 3).
Clinical impact of nonsusceptibility in
uropathogens among patients with UTIs
Since there was no 14-day mortality among enrolled
patients, clinical impact will be referred to the length of
hospital stays. The hospital stay was longer in UTI due to
levofloxacin-nonsusceptible (16.1  10.9 vs. 7.5  3.6 days;
p < 0.01), cefazolin-nonsusceptible (15.4  9.8 vs.
8.4  6.2 days; p < 0.01), or ESBL-producing (16.7  10.9
vs. 9.6  7.3 days; p < 0.01) uropathogens, as compared
with those due to antimicrobial-susceptible comparators.
Discussion
In this study, among selected hospitalized adults with
microbiologically documented CoUTIs, we identified
several host factors that are helpful in the differentiation
of UTIs due to antimicrobial-nonsusceptible uropathogens
from antimicrobial susceptible uropathogens. In general,
male gender, recent hospitalization, and underlying old
stroke were independently associated with the acquisition
of levofloxacin- or cefazolin-nonsusceptible uropathogens.
Typical presentations of urosepsis, such as urinary symp-
toms, fever, chills, though with variable statistical signifi-
cance in the multivariate analysis, were related to UTIs due
to levofloxacin- or cefazolin-susceptible uropathogens.
Moreover, the acquisition of levofloxacin- or cefazolin-
nonsusceptible uropathogens, although no short-term
survival impact was seen in our study, was related to
a longer hospital stay, which could be anticipated to
increase medical cost. A similar impact was observed in the
population acquiring ESBL-producer UTIs, in which theywere independently associated with prior hospitalization,
nursing home residence or regularly visiting dialysis centers
and recent antibiotic exposure, comparable to the findings
of a Canadian study.9
Our study population was designed to include the
patients with CoUTIs. As evidenced by the frequent pres-
ence of a history of recent visits to healthcare facilities and
functional or structural disorders in the urinary tract, our
patients were not initially healthy, as defined in the
patients with community-acquired infections. More
precisely, some of our enrolled patients had community-
onset, healthcare-associated UTIs, rendering a certain
degree of heterogeneity in the study cohort. However, such
a heterogeneous population was frequently encountered in
the referral tertiary hospitals.
Although cefazolin is not recommended as empirical
therapy for community-acquired UTIs in the clinical
guidelines from western countries, in Taiwan it still plays an
important role as one of the drugs of choice for acute
uncomplicated or complicated pyelonephritis in adults.10
Although clinical data of antimicrobial therapy and anti-
microbial susceptibility among uropathogens in adults are
scarce, such information from pediatric population in
Taiwan is available. Among 446 E. coli isolates obtained
from 597 pediatric cases of UTIs, cefazolin resistance was
noted in 24% of patients, but nearly 40% of the affected
children had underlying GU tract anomalies, which predis-
posed them to recurrent UTI and previous antimicrobial
therapy.11 Moreover, in a retrospective analysis of 338
children with the first episodes of symptomatic UTIs,
cefazolin, or cephalexin alone was regarded to be an
appropriate treatment for community-acquired UTIs,12
supporting the rationale that cefazolin can be one of the
alternative drugs for CoUTIs in adults without the risk
factors of cefazolin nonsusceptibility identified in our
study.
The interaction between clinical presentations of UTIs
and antimicrobial susceptibility of causative pathogens was
Levofloxacin and cefazolin nonsusceptibility in community-onset uropathogens 203rarely mentioned. We found that UTIs due to antimicrobial-
nonsusceptible isolates cause less local or systemic symp-
toms/signs such as urinary irritation, fever, or chills, as
compared with UTIs caused by susceptible comparators.
There is a possibility that antimicrobial-nonsusceptible UTIs
are often present in relatively debilitated elderly with
underlying chronic illness, and therefore their localized
symptoms are less evident clinically and febrile responses
are blunted.13 However, another plausible reason may be
the variable pathogenicity among bacterial isolates with
varied degrees of antimicrobial resistance.8
There were several limitations in the present study.
First, the reported clinical impact of decreased antimicro-
bial susceptibility among uropathogens was limited to the
hospital stay, but in fact may involve increasing medical
cost and morbidity and mortality which were not investi-
gated in our study. Second, the appropriateness of thera-
peutic regimens for CoUTIs, which in theory would
influence clinical responses of medical therapy and there-
after the hospital stay, were not examined. However, none
of our study population had in-hospital mortality or needed
intensive care for critical illness.
With the knowledge of host factors associated with
antimicrobial nonsusceptibility in uropathogens, physicians
can select appropriate empirical therapy for patients with
UTIs due to these pathogens. The clinical impact posed by
these antimicrobial-resistant uropathogens warrants
further studies.
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